Back to Search
LINDA VAHDAT, MD
MD
Medical Oncology Physician
NPI: 1871680942IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
176537(NY)22394(NH)
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
176537(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
OTHER
Class of 1987
Research & Publications (20)
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
PMID 19351752·Clin Cancer Res·2009
3-trial
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
PMID 19349550·J Clin Oncol·2009
3-trial
Angiomodulin is a specific marker of vasculature and regulates vascular endothelial growth factor-A-dependent neoangiogenesis.
PMID 19542015·Circ Res·2009
7-preclinical
Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.
PMID 19460418·Biochim Biophys Acta·2009
6-review
Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.
PMID 19153124·Ann Oncol·2009
3-trial
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
PMID 19103723·J Clin Oncol·2009
8-other
The influence of potassium clavulanate on the rate of amoxicillin sodium degradation in phosphate and acetate buffers in the liquid state.
PMID 19048426·Drug Dev Ind Pharm·2009
8-other
Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.
PMID 18043899·Breast Cancer Res Treat·2008
8-other
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
PMID 18086794·J Clin Oncol·2008
8-other
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
PMID 19158037·Clin Breast Cancer·2008
6-review
Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?
PMID 18762793·Nat Clin Pract Oncol·2008
8-other
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
PMID 18650153·Clin Breast Cancer·2008
3-trial
Epothilones: clinical update and future directions.
PMID 18472615·Oncology (Williston Park)·2008
6-review
Clinical studies with epothilones for the treatment of metastatic breast cancer.
PMID 18410796·Semin Oncol·2008
6-review
Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
PMID 18378531·Oncologist·2008
6-review
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
PMID 17606975·J Clin Oncol·2007
3-trial
Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
PMID 17972174·Breast Cancer Res Treat·2007
5-case
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
PMID 17968020·J Clin Oncol·2007
3-trial
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
PMID 17785568·Clin Cancer Res·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1 MEDICAL CENTER DRIVE
LEBANON, NH 03756 - Phone
- (603) 650-5747
Quick Facts
- NPI
- 1871680942
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 39
- Publications
- 20
Are you this provider?
Claim Your Profile